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Objective: To explore the complex issue of competing interests (CIs) in development of clinical 
practice guidelines (CPGs) in diabetes with stakeholders.
Methods: A multidisciplinary panel of 26 health, methodological, legal, and bioethical experts, 
trainees, and lay people from across Canada participated in a workshop on CIs in CPGs. Mixed 
methods were used such that qualitative themes were extracted from the discussions and quan-
titative survey data were collected.
Results: In the discussions, participants acknowledged that potential competing interests were 
not uncommon among sponsoring organizations and authors of CPGs. Avoidance of all potential 
CIs in development of CPGs was emulated as ideal, but considered probably unrealistic, given 
the paucity of peer-reviewed funding opportunities for development of evidence-informed 
CPGs and the scarcity of knowledgeable authors without CIs. An optimal approach for manage-
ment of CIs in CPGs could not be agreed upon by participants. Full disclosure of any ﬁ  nancial 
CIs for authors and sponsoring organizations as well as discouragement of external ﬁ  nancial 
contributors from writing involvement, were endorsed by participants in the workshop and a 
subsequent survey.
Conclusions: Complete disclosure of ﬁ  nancial CIs of sponsoring organizations and authors 
of CPGs is essential, yet the optimal approach to management of potential CIs is currently 
undeﬁ  ned.
Keywords: conﬂ  icts of interest, clinical practice guidelines, diabetes, knowledge translation, 
bioethics
Introduction
Serious concerns about competing interests (CIs) in diabetes-related clinical practice 
guideline (CPG) development have recently been voiced in the medical literature 
(Editorial [Canadian Medical Association Journal] 2005). Although CIs may take 
many forms, ﬁ  nancial relationships of clinicians, scientists, and professional or disease-
related organizations with industry have been the main focus of recent literature. 
In Canada, in the ﬁ  eld of diabetes, the presence of undisclosed potential CIs of the 
authors of a CPG sponsored by the Canadian Diabetes Association was criticized in 
recent years (Editorial 2005). The speciﬁ  c criticism (Editorial 2005) stemmed from 
differences in recommendations on the use of a particular insulin formulation in the 
Canadian Diabetes Association (CDA) clinical practice guideline (Canadian Diabetes 
Association Clinical Practice Guidelines Expert Committee 2003), compared with 
those of a national drug formulary (Common Drug Review) (Canadian Coordinating 
Ofﬁ  ce for Health Technology Assessment 2005). The implication of the criticism was 
that undisclosed CIs of authors of the CDA guideline could potentially account for 
some of the differences in recommendations observed.Journal of Multidisciplinary Healthcare 2008:1 30
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Relationships between industry and the authors of CPGs 
or specialty medical organizations are not uncommon, and 
may be under-reported. In a review of clinical guidelines 
published in six major medical journals in 1979, 1984, 
1989, 1994, and 1999, only 3.7% of guidelines mentioned 
CIs (Papanikolaou et al 2001). Furthermore, in a cross-
sectional survey of 192 authors of 44 CPGs endorsed by 
North American and European societies on common adult 
diseases published between 1991 and 1999, an average of 
81% of authors per clinical practice guideline had interac-
tions with industry and the average author interacted with 
10.5 different companies (Choudhry et al 2002). In a survey 
of Australian medical organizations, 59% of organizations 
reported receiving support from one or more pharmaceuti-
cal companies (Kerridge et al 2005). In a review of 200 
guidelines deposited in the US National Guideline Clear-
inghouse in 2004, investigators from the journal, Nature, 
found that 35% of authors disclosed a conﬂ  ict of interest, 
16% of authors helped write guidelines on illnesses rel-
evant to companies in which they owned stock, and 49% 
of guidelines did not include any details of authors’ CIs 
(Taylor and Giles 2005). Moreover, an editor of the Journal 
of the American Medical Association has stated that, “drug 
company sponsors see guideline-issuing bodies as perfect 
places to exert inﬂ  uence” (Taylor and Giles 2005). Such 
criticisms have led to questions such as “can we trust the 
evidence in evidence-based medicine?”, pertaining speciﬁ  -
cally to evidence-based guideline development (Abramson 
and Starﬁ  eld 2005).
Our aim was to assemble a multidisciplinary, multi-
institutional, panel of experts, students, and lay people from 
across Canada to explore the issue of CIs in development 
and dissemination of CPGs, particularly focusing on diabetes 
care. The participants were identiﬁ  ed as stakeholders in this 
issue, because of their clinical, academic, or methodologic 
focus, or because they acted as representatives of individu-
als with diabetes. Mixed methods, including qualitative and 
quantitative approaches were used in analyzing data that 
was collected.
Methods
Format of the workshop and qualitative 
methodology
A half-day workshop was held in Toronto, Canada on 
October 18, 2006. We invited health, methodological, 
legal, and bioethical experts, trainees, and lay people from 
across Canada. Four structured lectures 20–30 minutes in 
duration were each followed by open discussion periods, 
moderated by two investigators (AMS and AG). The 
proceedings were audio recorded, with the exception of 
one lecture, as per the request of the speaker. The session 
was closed to the public. All participants were informed 
that their personal views would not be identiﬁ  ed outside 
the group and open discussion was encouraged. When 
necessary, the discussions were refocused onto relevant 
concepts, with acknowledgement of the presence of some 
conﬂ  icting views.
An approach founded in Delphi methodology was used in 
developing summary statements (Jones and Hunter 1995). A 
strict consensus was not the goal, given the sensitivity of the 
topic and the known conﬂ  icting views of some of the selected 
participants. A qualitative researcher (LM) and a research 
assistant took notes during the session, to supplement audio-
recordings of the sessions. Relevant themes from the discus-
sions and notes were extracted by the qualitative researcher 
(LM). The ﬁ  nal theme summary statements were compiled by 
two of the investigators (LM and AS) using the data extracted 
by the qualitative researcher in her structured notes.
Survey several months 
after the workshop
A few months after the session, a self-administered survey 
summarizing key themes from the discussions was distributed 
to participants via electronic mail. In the questionnaire, sum-
mary statements were accompanied by a Likert scale, framed 
on a disagree – agree continuum (Streiner and Norman 1995), 
on a scale of 1 to 7 (with the value of 7 representing the 
strongest agreement). We deﬁ  ned “general strong agreement” 
with statements by a value of 5 or greater out of seven in all 
participants. “Opinion dissent” was reﬂ  ected by agreement 
scores ranging from 3 to 4 among participants. “Some 
agreement” was deﬁ  ned by all agreement scores ranging 
from 4 to 7 among all participants. The means and standard 
deviations and ranges for agreement to Likert scale ques-
tions were calculated (SPSS 12.0; SPSS Inc., Chicago, IL). 
Completed ﬁ  nal questionnaires were returned via electronic 
mail or fax as per respondent preference.
Results
Description of participants 
and the framework of the discussions
Twenty-six participants in the workshop included experts 
in: health (diabetes and other diseases), methodology 
(epidemiology, knowledge synthesis, knowledge translation, Journal of Multidisciplinary Healthcare 2008:1 31
Competing interests and clinical practice guidelines
biostatistics, and health economics), medical writing, 
health law, bioethics, and administration (related to a 
disease organization). Health experts were from multiple 
areas including endocrinology, medicine, primary care, 
ophthalmology, ethics, nursing, and nutrition. Authors of 
clinical practice guidelines (in diabetes and other diseases) 
participated. A patient representative and trainees in 
medicine-related specialties or ethics also participated. 
Representatives of the CDA as well as other disease 
organizations sponsoring clinical practice guidelines were 
included. Individuals with and without relationships with 
industry were included.
Qualitative theme #1: Multifaceted 
potential competing interests 
and disclosure
The existence of CIs among sponsoring organizations and 
authors of CPGs were recognized to be common. Some par-
ticipants point out that, potential CIs could be multifaceted, 
including ﬁ  nancial, academic, political, religious, cultural, 
personal, professional, or other organizational interests. The 
potential importance of nonﬁ  nancial CIs was stressed by 
some participants. The identiﬁ  ed sources of ﬁ  nancial CIs 
were thought to include industry, governments, third party 
payers, or other organizations. The optimal term for descrip-
tion of competing interests could not be agreed upon, with 
a few participants preferring the term, “duality of interest.” 
Disclosure was used to describe the process of declaring 
potential CIs. The importance of disclosure of any ﬁ  nancial 
CIs of sponsoring organizations or authors in the planning 
and development stages of CPGs was strongly asserted to 
be important by multiple participants. Furthermore, several 
participants stressed the importance of publicly disclosing 
CIs related to sponsoring organizations of CPGs and their 
authors. The lack of public disclosure of all ﬁ  nancial CIs 
of sponsoring organizations and authors of CPGs was 
considered a threat to professional credibility and public 
trust in the CPG by some participants.
Qualitative theme #2:   The importance 
of putting the evidence ﬁ  rst in CPG 
recommendations
Multiple participants asserted that CPG recommendations 
should be evidence-based, although it was acknowledged 
that some primary research evidence may be prone to CIs. 
The use of systematic techniques in reviewing and apprais-
ing existing evidence was encouraged by some participants. 
The incorporation of economic analyses in all CPGs was not 
thought to be feasible, because of lack of human and ﬁ  nancial 
resources to carry out such analyses properly and regional 
variability in costs, affordability, and values. The great 
ﬁ  nancial cost of producing high quality, evidence-informed 
CPGs was stressed my individuals involved in development 
of such guidelines as well as representatives of sponsoring 
organizations.
Qualitative theme #3: Can competing 
interests be avoided in development 
of clinical practice guidelines?
Some participants suggested that all potential ﬁ  nancial 
CIs should ideally be avoided in development of CPGs. 
Concerns were expressed on the potential inﬂ  uence of 
relationships of physicians and the pharmaceutical industry, 
consciously or unconsciously, impacting recommendations. 
However, most participants conceded that avoidance of 
all ﬁ  nancial CIs of sponsoring organizations or authors 
of CPGs, although ideal, may not be feasible at this time. 
The high need for ﬁ  nancial and human resources in devel-
oping and disseminating high quality CPGs and the lack 
of peer-reviewed independent funding for such purposes, 
were acknowledged as important challenges. Furthermore, 
the contribution of knowledge and expertise from authors 
with known CIs, was highlighted by several participants. 
The scarcity of clinical content or methodologic experts 
without CIs was asserted. Thus, strict exclusion of all 
experts with CIs from CPG development could not be 
endorsed by most members of the group. This issue was 
subject to some opinion debate. However, independence of 
authorship and writing editing of a guideline, without any 
direct input of ﬁ  nancial supporters was strongly supported 
by multiple participants.
Quantitative survey data
A survey was distributed to participants several months after 
the workshop. In this survey, issues that were discussed at the 
session were summarized in the form of summary statements. 
The response rate to this self-administered survey was 57.7% 
(15/26). A summary of the responses is shown in Table 1. We 
observed strong general agreement with statements relating 
to the deﬁ  nition of disclosure and the suggestion that CIs 
should be declared by sponsoring organizations and authors 
in the planning stage of a CPG. There was some agreement 
with statements suggesting that the development of CPGs 
is important and should not be abandoned as a knowledge Journal of Multidisciplinary Healthcare 2008:1 32
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Table 1 Results of an opinion survey several months after the workshop
Statement (number of responses, maximum 15) Likert scale agreementa 
Mean (Standard deviation) 
(Range of values)
Classiﬁ  cationb
1. The term “competing interests” reasonably reﬂ  ects 
various potential multifaceted interests of organizations 
or authors of clinical practice guidelines. (15)
4.9 (1.5)
(2, 7)
Opinion dissent
2. Competing interests may include ﬁ  nancial, academic, 
political, cultural, religious, or other personal or organi-
zational interests related to a topic. (15)
6.1 (1.3)
(2, 7)
Opinion dissent
3. Disclosure is the process of declaring competing 
interests. (15)
6.5 (0.6)
(5, 7)
General strong agreement
4. The presence of undisclosed, unaddressed, compet-
ing interests may threaten: a) the credibility of clinical 
practice guidelines among healthcare professionals and 
b) the public’s trust. (15)
6.1 (1.3)
(3, 7)
Opinion dissent
5. Ideally, in the planning of a clinical practice guide-
line, a dedicated (internal or external) advisory panel 
should be established to evaluate, monitor, record, and 
ultimately disclose any competing interests related to 
the guideline or its authors. (15)
4.9 (1.6)
(2, 7)
Opinion dissent
6. Competing interests should be declared by sponsor-
ing organizations and authors in the planning stage of a 
clinical practice guideline. (15)
6.6 (0.6)
(6, 7)
General strong agreement
7. Contributing authors of a clinical practice guideline 
should be informed of the competing interests of the 
sponsoring organization as well as other coauthors in 
the planning stage of the guideline. (15)
6.3 (0.9)
(4, 7)
Some agreement
8. Disclosure of competing interests related to clinical 
practice guidelines should be made public upon release 
of the guideline. (14)c
6.4 (0.9)
(4, 7)
Some agreement
9. Ideally, the presence of competing interests should be 
minimized for clinical practical guidelines, but complete 
avoidance of all potential conﬂ  icts of interests for 
sponsoring organizations and authors may not always 
be possible. (15)
5.5 (1.8)
(1, 7)
Opinion dissent
10. If there are external ﬁ  nancial contributors for a 
clinical practice guideline, such supporters should 
not be involved in any aspect of writing of the 
guideline. (15)
6.6 (0.9)
(4, 7)
Some agreement
11. Our group did not reach consensus on a threshold 
at which a contributing author has excessive competing 
interests precluding involvement in development of a 
clinical practice guideline. (15)
6.0 (0.9)
(4, 7)
Some agreement
12. Recommendations in clinical practice guidelines 
should be evidence-based, although it is acknowledged 
that some primary research evidence may prone to 
competing interests. (15)
5.7 (1.0)
(4, 7)
Some agreement
13. Although the inclusion of economic analyses explor-
ing the cost of recommendations of clinical practice 
guidelines may be ideal, it may not be currently feasible 
for all clinical practice guidelines because of lack of 
human and ﬁ  nancial resources to carry out such analy-
ses properly as well as regional variability in costs and 
values that might affect affordability of recommenda-
tions. (15)
5.9 (0.9)
(4, 7)
Some agreementJournal of Multidisciplinary Healthcare 2008:1 33
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14. Future research is needed to develop innovative 
strategies to deal with competing interests in clinical 
practice guideline development. (15)
5.6 (1.6)
(3, 7)
Opinion dissent
15. Future research is needed to develop effective 
knowledge translation strategies for dissemination and 
accurate representation of clinical practice guideline 
recommendations. (15)
6.3 (0.9)
(4, 7)
Some agreement
16. The development of clinical practice guidelines is 
important and should not be abandoned as a knowl-
edge translation strategy aimed at healthcare profes-
sionals. (15)
6.6 (1.1)
(4, 7)
Some agreement
Notes: aFor Likert scale questions, a score of 1 represented strong disagreement, whereas a maximal score of 7 represented the strongest agreement. bWe deﬁ  ned “general 
strong agreement” with statements by a value of 5 or greater out of seven in all participants. “Opinion dissent” was reﬂ  ected by agreement scores ranging from 3 to 4 
among participants. “Some agreement” was deﬁ  ned by all agreement scores ranging from 4 to 7 among all participants. cOne blank response.
translation strategy aimed at healthcare professionals. Some 
agreement was also observed with a suggestion that research 
needs to be aimed at developing effective knowledge transla-
tion strategies for dissemination and accurate representation 
of CPG recommendations. Respondents generally agreed that 
CPG recommendations should be evidence-based, without 
the absolute requirement of economic analyses. There was 
some agreement with statements suggesting that ﬁ  nancial 
contributors be excluded from any aspect of writing of a 
CPG and that disclosure of CIs be made public. Opinion 
dissent was expressed with respect to the following issues: 
competing interests terminology, the multifaceted composi-
tion of CIs, the impact of CIs on the credibility of a CPG, and 
public trust, the suggestion of an advisory panel monitoring 
CPGs for sponsoring organizations, and the feasibility of 
strict avoidance of CIs.
Discussion
We assembled a Canadian multidisciplinary panel and 
explored the concept of competing interests in development 
and dissemination of CPGs. Our ﬁ  ndings highlighted the 
complexity and sensitivity of stakeholders to his issue. The 
need for transparency and disclosure of CIs of sponsoring 
organizations and authors of CPGs were highlighted in 
the qualitative and quantitative data collected. However, 
considerable opinion dissent was observed with respect to 
the issues of threshold of acceptability of CIs for authors 
and sponsoring organizations writing CPGs and the impact 
of CIs on the credibility of recommendations. Concerns 
were expressed on the potential inﬂ  uence of relationships 
of physicians and the pharmaceutical industry, consciously 
or unconsciously, impacting recommendations. It is impor-
tant to acknowledge that in a prior review paper, Wazana 
(2000) reported that physician meetings with pharmaceutical 
representatives were associated with changes in drug 
formularies and prescribing behavior. However, evidence-
based approaches to developing CPG recommendations 
were favored in CPG development by our group in hopes 
of minimizing bias. Yet, the use of such approaches may 
not necessarily safeguard CPGs from the inﬂ  uence of CIs, 
as primary research and its interpretation may be subject 
to potential inﬂ  uences of CIs. For example, it has been 
reported in the literature that industry sponsorship of studies 
is associated with pro-industry conclusions (Bekelman et al 
2003). An optimal, feasible approach to minimizing the 
impact of CIs on CPG development could not be agreed 
upon in our group. In the interim, transparency of process 
and full disclosure of CIs were deemed essential for the 
credibility of CPGs
The strengths of our workshop ﬁ  ndings are that we 
were able to assemble a multidisciplinary panel of experts, 
trainees, and a lay person from a variety of backgrounds 
to openly discuss a highly complex, sensitive topic that 
inﬂ  uences clinical care in diabetes care and other con-
ditions. Furthermore, we were able to secure a closed 
environment, stimulating frank (and at times heated) 
debate among individuals with a variety of perspectives. 
Limitations of our study included: the lack of any strict 
consensus recommendations, a limited response rate to our 
post-workshop questionnaire, and the lack of international 
participants. We suspect that the relatively low response 
rate to our post-workshop questionnaire may be due to the 
sensitivity of the topic.
In terms of future research directions, it would be instruc-
tive for a multidisciplinary panel of stakeholders involved 
in management of other disease conditions, to explore opin-
ions on the issue of CIs in CPGs. Also, qualitative research 
exploring the opinions of lay people on this issue would be Journal of Multidisciplinary Healthcare 2008:1 34
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valuable. In the mean time, core values including, an ethically 
conscious, evidence-informed, transparent approach in the 
development of CPGs has been emphasized in our study, in 
absence of any strict consensus on the threshold of acceptance 
(or rejection) for CIs in CPGs.
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